MSLN and triple-negative breast carcinoma: RG7787-conjugated MSLN is being evaluated in phase I clinical trials on patients with MSLN-positive malignancies, including mesothelioma and ovarian, pancreatic, gastric, and triple-negative breast cancer (TNBC) (Table 2) (44).